Cyclic GMP modulating drugs in cardiovascular diseases: Mechanism-based network pharmacology

Alexandra Petraina*, Cristian Nogales, Thomas Krahn, Hermann Mucke, Thomas F Lüscher, Rodolphe Fischmeister, David A Kass, John C Burnett, Adrian J Hobbs, Harald H H W Schmidt

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

58 Downloads (Pure)

Abstract

Mechanism-based therapy centred on the molecular understanding of disease-causing pathways in a given patient is still the exception rather than the rule in medicine, even in cardiology. However, recent successful drug developments centred around the second messenger cyclic guanosine-3'-5'-monophosphate (cGMP), which is regulating a number of cardiovascular disease modulating pathways, are about to provide novel targets for such a personalised cardiovascular therapy. Whether cGMP breakdown is inhibited or cGMP synthesis is stimulated via guanylyl cyclases or their upstream regulators in different cardiovascular disease phenotypes, the outcomes seem to be so far uniformly protective. Thus, a network of cGMP modulating drugs has evolved that act in a mechanism-based, possibly causal manner in a number of cardiac conditions. What remains a challenge is the detection of cGMPopathy endotypes amongst cardiovascular disease phenotypes. Here we review the growing clinical relevance of cGMP and provide a glimpse into the future on how drugs interfering with this pathway may change how we treat and diagnose cardiovascular diseases altogether.

Original languageEnglish
Pages (from-to)2085-2102
Number of pages18
JournalCardiovascular Research
Volume118
Issue number9
Early online date16 Jul 2021
DOIs
Publication statusPublished - 20 Jul 2022

Keywords

  • Guanylate cyclase
  • Natriuretic peptides
  • Nitric oxide
  • Cyclic GMP
  • Biomarkers
  • SOLUBLE GUANYLATE-CYCLASE
  • ATRIAL-NATRIURETIC-PEPTIDE
  • PRESERVED EJECTION FRACTION
  • HEART-FAILURE PATIENTS
  • NITRIC-OXIDE SYNTHASE
  • ASSOCIATION TASK-FORCE
  • ASYMMETRIC DIMETHYLARGININE ADMA
  • VASCULAR SUPEROXIDE-PRODUCTION
  • 2013 ACCF/AHA GUIDELINE
  • QUALITY-OF-LIFE

Cite this